palovarotene   Click here for help

GtoPdb Ligand ID: 8276

Synonyms: CLM-001 | IPN-60120 | IPN60120 | R-667 | R667 | RG-667 | Ro-3300074 | Sohonos®
Approved drug
palovarotene is an approved drug (Canada (2022), FDA (2023))
Compound class: Synthetic organic
Comment: Palovarotene is an orally bioavailable, retinoic acid receptor gamma (RAR-γ) agonist. This compound was originally investegated for its potential to repair alveolar damage in emphysema and COPD [1,8], but it failed to demonstrate significant clinical efficacy. Ipsen acquired palovarotene when it purchased Clementia Pharmaceuticals in 2019, and they repurposed palovarotene for potential to reduce heterotopic ossification in patients with fibrodysplasia ossificans progressiva (FOP) [6,9].
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 3
Hydrogen bond donors 1
Rotatable bonds 5
Topological polar surface area 55.12
Molecular weight 414.23
XLogP 7.85
No. Lipinski's rules broken 1
Click here for help
Canonical SMILES OC(=O)c1ccc(cc1)C=Cc1cc2c(cc1Cn1cccn1)C(C)(C)CCC2(C)C
Isomeric SMILES OC(=O)c1ccc(cc1)/C=C/c1cc2c(cc1Cn1cccn1)C(C)(C)CCC2(C)C
InChI InChI=1S/C27H30N2O2/c1-26(2)12-13-27(3,4)24-17-22(18-29-15-5-14-28-29)21(16-23(24)26)11-8-19-6-9-20(10-7-19)25(30)31/h5-11,14-17H,12-13,18H2,1-4H3,(H,30,31)/b11-8+
Bioactivity Comments
Palovarotene dose-dependently suppresses heterotopic ossification in mice [7]. We have been unable to find a publicly available affinity value for this agonist at its proposed primary target, retinoic acid receptor gamma (RARG), so have tagged the primary target based on biological evidence.
Selectivity at nuclear hormone receptors
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
Retinoic acid receptor-γ Primary target of this compound Hs Agonist Agonist - - -